Kalvista Pharmaceuticals Inc - Asset Resilience Ratio
Kalvista Pharmaceuticals Inc (KALV) has an Asset Resilience Ratio of 19.32% as of October 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Kalvista Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Kalvista Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Kalvista Pharmaceuticals Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Kalvista Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Kalvista Pharmaceuticals Inc (KALV) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $65.66 Million | 19.32% |
| Total Liquid Assets | $65.66 Million | 19.32% |
Asset Resilience Insights
- Good Liquidity Position: Kalvista Pharmaceuticals Inc maintains a healthy 19.32% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Kalvista Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Kalvista Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Kalvista Pharmaceuticals Inc (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Kalvista Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-04-30 | 35.49% | $89.00 Million | $250.77 Million | -40.38pp |
| 2024-04-30 | 75.87% | $178.61 Million | $235.40 Million | +25.04pp |
| 2023-04-30 | 50.84% | $93.14 Million | $183.20 Million | -15.61pp |
| 2022-04-30 | 66.45% | $135.47 Million | $203.88 Million | -6.47pp |
| 2021-04-30 | 72.91% | $198.34 Million | $272.01 Million | +16.80pp |
| 2020-04-30 | 56.12% | $51.92 Million | $92.53 Million | -2.13pp |
| 2019-04-30 | 58.24% | $68.81 Million | $118.13 Million | -- |
| 2018-04-30 | 0.00% | $0.00 | $61.39 Million | -- |
| 2017-04-30 | 0.00% | $0.00 | $34.34 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $56.79 Million | -- |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more